CST, 78144S, LILRB1/CD85j (D4L8L) Rabbit Monoclonal Antibody

Monoclonal Antibody for studying LILRB1. Validated for Western Blotting. Available in 2 sizes. Highly specific and rigorously validated in-house, LILRB1/CD85j (D4L8L) Rabbit Monoclonal Antibody (CST #78144) is ready to ship. Product Usage Information Western Blotting: 1:1000 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Western Blotting Specificity / Sensitivity LILRB1/CD85j (D4L8L) Rabbit Monoclonal Antibody recognizes endogenous levels of total LILRB1/CD85J protein. This antibody does not cross-react with LILRB2 protein. Species Reactivity: Human Source / Purification Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Arg370 of human LILRB1/CD85j protein. Background The leukocyte Ig-like receptor subfamily B (LILRB) are type-I transmembrane glycoproteins containing ligand-binding extracellular IgG-like domains and immunoreceptor tyrosine-based inhibition motifs (ITIMS) within the cytoplasmic domain, which recruit SHP protein tyrosine phosphatases, leading to transduction of signals that inhibit immune cell activation. Encoded within a region of chromosome 19 known as the leukocyte receptor complex, the LILRB subfamily of inhibitory receptors consists of LILRB1 to LILRB5, also referred to as CD85J, CD85D, CD85A, CD85K, and CD85C, respectively (1). There is mounting evidence that LILRBs function, in part, as a novel class of immune checkpoint receptors and support tumor growth through the transmission of inhibitory signals upon engagement of ligands expressed on tumor cells (2). LILRB1 (CD85j/ILT2/LIR1) is expressed across multiple hematopoietic cell lineages, such as B-cells, NK cells, monocytes, and T-cells (3,4). Like other members of the LILRB subfamily, LILRB1 contains multiple extracellular IgG-like domains and intracellular ITIM motifs (5). Research studies have demonstrated that LILRB1 interacts with multiple HLA class I ligands, such as HLA-G (6). Cross-linking of LILRB1 upon ligand engagement has been shown to activate immunosuppressive signaling cascades, which in B-cells, suppresses their activation and ability to produce antibodies (7). In NK and T cell lineages, research studies have shown that LILRB1 transduces signaling to inhibit cytolytic activity (3). Alternate Names CD85; CD85 antigen; CD85 antigen-like family member J; CD85J; FLJ37515; Ig-like transcript 2; ILT-2; ILT2; Immunoglobulin-like transcript 2; leucocyte Ig-like receptor B1; leukocyte Ig-like receptor-1; leukocyte immunoglobulin like receptor B1; Leukocyte immunoglobulin-like receptor 1; Leukocyte immunoglobulin-like receptor subfamily B member 1; leukocyte immunoglobulin-like receptor subfamily B member 1 soluble isoform; leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 1; LILRB1; LIR-1; LIR1; LIRB1; MIR-7; MIR7; Monocyte/macrophage immunoglobulin-like receptor 7; myeloid inhibitory receptor 7; PIR-B; PIRB Specification REACTIVITY: H SENSITIVITY: Endogenous MW (kDa): 110 Source/Isotype: Rabbit IgG